Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$397.49 USD

397.49
467,049

+14.72 (3.85%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks News

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix

The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.

United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag

United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.

Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF

United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Lags Q1 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

United Therapeutics (UTHR) Misses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.